| Literature DB >> 34099676 |
Maysam Mansouri1, Marie-Didiée Hussherr1, Tobias Strittmatter1, Peter Buchmann1, Shuai Xue1, Gieri Camenisch1, Martin Fussenegger2,3.
Abstract
Wearable smart electronic devices, such as smart watches, are generally equipped with green-light-emitting diodes, which are used for photoplethysmography to monitor a panoply of physical health parameters. Here, we present a traceless, green-light-operated, smart-watch-controlled mammalian gene switch (Glow Control), composed of an engineered membrane-tethered green-light-sensitive cobalamin-binding domain of Thermus thermophilus (TtCBD) CarH protein in combination with a synthetic cytosolic TtCBD-transactivator fusion protein, which manage translocation of TtCBD-transactivator into the nucleus to trigger expression of transgenes upon illumination. We show that Apple-Watch-programmed percutaneous remote control of implanted Glow-controlled engineered human cells can effectively treat experimental type-2 diabetes by producing and releasing human glucagon-like peptide-1 on demand. Directly interfacing wearable smart electronic devices with therapeutic gene expression will advance next-generation personalized therapies by linking biopharmaceutical interventions to the internet of things.Entities:
Year: 2021 PMID: 34099676 DOI: 10.1038/s41467-021-23572-4
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919